Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for injury repair.
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soluble Uric Acid Drives CD8+ T-cell Exhaustion by Inducing KSR1-Mediated MAPK Hyperactivation.

Cancer research·2026
Same author

USP10 Dysregulation in Oncogenic Virus-Driven Tumourigenesis and Immune Evasion.

Reviews in medical virology·2026
Same author

Ryder: Epigenome normalization using a two-tier model and internal reference regions.

bioRxiv : the preprint server for biology·2026
Same author

Chromatin reorganization drives overexpression of a Btaf1 variant underpinning hematopoietic aging.

Nature communications·2026
Same author

PKM2 phosphorylation by c-SRC activates glycolysis and metastasis with the stimulation of tumor-associated macrophages.

Cell communication and signaling : CCS·2026
Same author

Sequencing and health data resource of children of African ancestry.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Related Experiment Video

Updated: Jun 8, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Cell fate determination factor Dachshund reprograms breast cancer stem cell function.

Kongming Wu1, Xuanmao Jiao, Zhaoming Li

  • 1Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. kmwu2005@gmail.com

The Journal of Biological Chemistry
|October 13, 2010
PubMed
Summary

Dachshund homolog 1 (DACH1) suppresses breast tumor-initiating cells (BTICs). Loss of DACH1 correlates with poor prognosis in breast cancer, suggesting DACH1 as a therapeutic target for reducing tumor growth and resistance.

More Related Videos

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Jun 8, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Dachshund homolog 1 (DACH1) is a cell fate determination factor.
  • Loss of DACH1 expression is linked to poor prognosis in human breast cancer.
  • Breast tumor-initiating cells (BTICs) drive tumor progression and therapy resistance.

Purpose of the Study:

  • To investigate the role of DACH1 in regulating breast tumor-initiating cells.
  • To determine the impact of DACH1 re-expression or knockdown on BTIC properties.
  • To elucidate the molecular mechanisms by which DACH1 controls BTIC populations.

Main Methods:

  • Analysis of endogenous DACH1 levels in breast cancer cell lines and patient samples.
  • In vivo serial transplantation and in vitro mammosphere formation assays.
  • Genome-wide expression studies and ChIP-seq to identify DACH1 targets.
  • Mechanistic studies on DACH1's interaction with stem cell-associated gene promoters.

Main Results:

  • Endogenous DACH1 was reduced in breast cancer cells with high TIC markers and basal phenotype.
  • DACH1 re-expression reduced tumor formation, mammosphere formation, and CD44(high)/CD24(low) cells.
  • DACH1 knockdown increased the BTIC population.
  • DACH1 repressed stem cell-associated genes (SOX2, Nanog, KLF4) by binding to their promoters.
  • KLF4/c-Myc and Oct4/Sox2 antagonized DACH1's repressive effects.

Conclusions:

  • Endogenous DACH1 functions as a critical regulator of breast tumor-initiating cells.
  • DACH1 represses stem cell-associated genes, thereby inhibiting BTIC activity.
  • DACH1's role in controlling BTICs suggests its potential as a therapeutic target in breast cancer.